[CLSTR]
API
< Back to situations

[PERSON]

daraxonrasib

Featured in 11 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [ES] [KR] [GR]

ESMO 2026 oncology congress developments

3 clusters · 86 sources · last updated

Latest: ESMO Congress reveals major advancements in cancer treatment

The European Society for Medical Oncology (ESMO) 2026 congress in Madrid presented various phase 3 clinical trial results across multiple cancer types. Initial reports highlighted advancements in melanoma, where combini

[QUIET] [HEALTH] [US] [IT] [GR]

FDA approves Rasonque; EMA recommends for pancreatic cancer

44 clusters · 321 sources · last updated

Latest: Pancreatic cancer: New research and treatment developments in Greece

On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R

[QUIET] [HEALTH] [DE] [IT] [US]

Daraxonrasib development for pancreatic cancer

2 clusters · 5 sources · last updated

Latest: EMA recommends Daraxonrasib for advanced pancreatic cancer treatment

In September 2026, Felice Antonio Spaccavento, a health official in the Puglia region of Italy, formally requested that the Italian Medicines Agency (AIFA) accelerate access to the targeted therapy daraxonrasib. The requ

Also covered in